CGEM Cullinan Therapeutics, Inc.
Price Chart
Executive Summary
Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its CLN-049, a FLT3xCD3 T cell engager, for relapsed/refractory acute myeloid leukemia (AML). ODD provides development incentives, including tax credits, fee exemptions, and potential seven-year U.S. market exclusivity upon approval, but is a procedural milestone with limited direct stock impact for a clinical-stage biotech.
Actionable Insight
ODD is a modest positive catalyst — it lowers future development cost but does not change clinical probability of success. Phase 1 data updates in coming quarters will be the next price-relevant catalyst. The buy-side consensus is heavily bullish (95% strong buy/buy), suggesting limited incremental surprise from this news.
Key Facts
- FDA granted Orphan Drug Designation to CLN-049 for relapsed/refractory AML
- ODD provides tax credits, FDA fee exemptions, and potential 7-year exclusivity
- CLN-049 is a novel FLT3xCD3 T cell engager targeting both mutated and non-mutated FLT3
- CLN-049 is in Phase 1 trials (NCT05143996, EUCT 2023-506572-27-00) and has Fast Track designation
- Approximately 22,000 new AML cases/year in the U.S.; 5-year survival in R/R is ~10% or less
Financial Impact
No financial figures disclosed. ODD reduces development costs via fee waivers and tax credits but provides no revenue or approval guarantee.
Risk Factors
- Phase 1 clinical development still ongoing; safety/efficacy failures remain the dominant risk
- AML competitive landscape includes approved targeted therapies (e.g., gilteritinib, midostaurin) and other bispecifics in development
- ODD does not guarantee accelerated approval or commercial success
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297322 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $12.04 awaiting T+5 | awaiting T+5 | — | $13.70 (+13.79%) |
|
Jun 10, 2026
3d ago
|
Press Release
| $13.20 awaiting T+5 | awaiting T+5 | — | $13.70 (+3.79%) |
|
Jun 8, 2026
5d ago
|
8-K
| $13.51 awaiting T+5 | awaiting T+5 | — | $13.70 (+1.44%) |
|
May 19, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
8-K
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $14.91 $13.44 | ▼ −9.86% | ▼ −8.95% | $13.70 (−8.12%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access